Abstract
In the last years, the oncologic research is focusing on the optimization of the clinical approach to the tumor disease, through the development of new therapeutic strategies combining currently used antineoplastic drugs to targeted delivery systems. In fact, due to the drugs poor selectivity for cancer cells, an highly aggressive style of dosing is necessary to eradicate tumors, causing severe toxicity to normal cells. Therefore, localized drug delivery would, ideally, improve the therapeutic efficacy, minimizing side effects. Mesoporous silica nanoparticles (MSNs) have been proposed as a promising class of versatile drug/DNA delivery vehicles, as well as efficient tools for fluorescent cell tracking. To date, the major limitation is that MSNs enter the cells regardless of a target-specific functionalization. Therefore, this review is aimed to give a brief up to date overview on mesoporous silica based-drug delivery vehicles, specifically applied to tumor therapy, giving particular emphasis to the importance of a targeting function grafted on the carrier surface, so to avoid an indiscriminate uptake by cells.
Keywords: Cancer therapy, Drug targeting, Folate receptor, Mesoporous silica nanoparticles.
Mini-Reviews in Medicinal Chemistry
Title:Mesoporous Silica Nanoparticles in Cancer Therapy: Relevance of the Targeting Function
Volume: 16 Issue: 9
Author(s): Luigi Pasqua, Antonella Leggio, Diego Sisci, Sebastiano Andò and Catia Morelli
Affiliation:
- Department of Pharmacy and Health and Nutritional Sciences, Via P. Bucci, cubo 34/B University of Calabria, 87036 Arcavacata di Rende (CS) Italy,Italy
Keywords: Cancer therapy, Drug targeting, Folate receptor, Mesoporous silica nanoparticles.
Abstract: In the last years, the oncologic research is focusing on the optimization of the clinical approach to the tumor disease, through the development of new therapeutic strategies combining currently used antineoplastic drugs to targeted delivery systems. In fact, due to the drugs poor selectivity for cancer cells, an highly aggressive style of dosing is necessary to eradicate tumors, causing severe toxicity to normal cells. Therefore, localized drug delivery would, ideally, improve the therapeutic efficacy, minimizing side effects. Mesoporous silica nanoparticles (MSNs) have been proposed as a promising class of versatile drug/DNA delivery vehicles, as well as efficient tools for fluorescent cell tracking. To date, the major limitation is that MSNs enter the cells regardless of a target-specific functionalization. Therefore, this review is aimed to give a brief up to date overview on mesoporous silica based-drug delivery vehicles, specifically applied to tumor therapy, giving particular emphasis to the importance of a targeting function grafted on the carrier surface, so to avoid an indiscriminate uptake by cells.
Export Options
About this article
Cite this article as:
Pasqua Luigi, Leggio Antonella, Sisci Diego, Andò Sebastiano and Morelli Catia, Mesoporous Silica Nanoparticles in Cancer Therapy: Relevance of the Targeting Function, Mini-Reviews in Medicinal Chemistry 2016; 16(9) . https://dx.doi.org/10.2174/1389557516666160321113620
| DOI https://dx.doi.org/10.2174/1389557516666160321113620 |
Print ISSN 1389-5575 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
On the Nature of the Tumor-Initiating Cell
Current Stem Cell Research & Therapy Biological Evaluation and Molecular Modeling of 3,4-dihydropyrimidine- 2(1H)-one Derivatives as Cytotoxic Agents on Breast Cancer In Vitro
Letters in Drug Design & Discovery Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities
Current Pharmaceutical Design Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Old and New Approaches to Target the Hsp90 Chaperone
Current Cancer Drug Targets Xenograft models of primary acute myeloid leukemia for the development of imaging strategies and evaluation of novel targeted therapies.
Current Pharmaceutical Biotechnology Micro-flow Immunosensor Based on Thin-film Interdigitated Gold Array Microelectrodes for Cancer Biomarker Detection
Current Drug Delivery Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Use of Grape Polyphenols for Promoting Human Health: A Review of Patents
Recent Patents on Food, Nutrition & Agriculture Design and Synthesis of Novel Thioethers Derived from 1,5-Diphenyl-6- thioxo-6,7-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-ones as Antiangiogenic Agents
Letters in Drug Design & Discovery Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Targeted Therapies for Advanced Non-Small Cell Lung Cancer
Combinatorial Chemistry & High Throughput Screening Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Insulin Therapy for Diabetes Epidemic: A Patent Review
Current Drug Delivery Improving the Development on New Cancer Treatments: Challenges and Opportunities
Drug Design Reviews - Online (Discontinued) Meet Our Editorial Board Member:
Current Cancer Drug Targets What are the Cancer Risks in BRCA Carriers Apart from Those Regarding the Breast and the Ovary?
Current Women`s Health Reviews Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets




